294647-97-5

Usage

Uses

OTAVA-BB 1364598 is used as a chemical compound in the field of drug development and medicinal chemistry research for its potential pharmacological activity. The specific applications and reasons for its use in different industries are as follows:
1. Used in Pharmaceutical Industry:
OTAVA-BB 1364598 is used as a potential therapeutic agent for its pharmacological properties, which are yet to be fully elucidated. It is employed in drug development to explore its potential as a treatment for various diseases and conditions.
2. Used in Medicinal Chemistry Research:
OTAVA-BB 1364598 is used as a research compound to study its chemical properties, interactions with biological systems, and potential applications in medicinal chemistry. It serves as a promising candidate for further investigation to understand its role in therapeutic interventions.
3. Used in Drug Discovery:
OTAVA-BB 1364598 is used as a starting point or a lead compound in the drug discovery process. Its unique chemical structure and potential pharmacological activity make it a valuable asset for identifying new drug targets and developing novel therapeutic agents.
4. Used in Chemical Synthesis:
OTAVA-BB 1364598 is used as a building block or intermediate in the synthesis of more complex chemical compounds. Its unique structure and properties can be leveraged to create new molecules with potential applications in various fields, including pharmaceuticals, materials science, and agrochemicals.

Upstream product

• 32111-34-5 4-(pyridine-2-yl)benzonitrile 
• 109-04-6 2-bromo-pyridine 
• 126747-14-6 4-cyanophenylboronic acid 

Downstream Products

• 294647-99-7 2-chloro-6-[4-(2-pyridyl)phenylmethylamino]purine 
• 294647-35-1 C₂₆H₃₂N₈ 
• 294647-99-7 2-chloro-6-[4-(2-pyridyl)phenylmethylamino]-purine 
• 294648-01-4 2-chloro-9-isopropyl-N-[[4-(2-pyridyl)phenyl]methyl]purin-6-amine 
• 486435-76-1 N-[4-(pyridin-2-yl)-phenylmethyl]-4-(4'-trifluoromethylbiphenyl-2-carbonylamino)-1-methyl-pyrrole-2-carboxylic acid amide 

Relevant academic research and scientific papers

Identification of Adenine and Benzimidazole Nucleosides as Potent Human Concentrative Nucleoside Transporter 2 Inhibitors: Potential Treatment for Hyperuricemia and Gout

To test the hypothesis that inhibitors of human concentrative nucleoside transporter 2 (hCNT2) suppress increases in serum urate levels derived from dietary purines, we previously identified adenosine derivative 1 as a potent hCNT2 inhibitor (IC50 = 0.64 μM), but further study was hampered due to its poor solubility. Here we describe the results of subsequent research to identify more soluble and more potent hCNT2 inhibitors, leading to the discovery of the benzimidazole nucleoside 22, which is the most potent hCNT2 inhibitor (IC50 = 0.062 μM) reported to date. Compound 22 significantly suppressed the increase in plasma uric acid levels after oral administration of purine nucleosides in rats. Because compound 22 was poorly absorbed orally in rats (F = 0.51%), its pharmacologic action was mostly limited to the gastrointestinal tract. These findings suggest that inhibition of hCNT2 in the gastrointestinal tract can be a promising approach for the treatment of hyperuricemia.

Purinenucleoside derivative modified in 8-position and medical use thereof

The present invention provides an 8-modified purinenucleoside derivative which is useful for diseases associated with an abnormality of plasma uric acid level. An 8-modified purinenucleoside derivative represented by the following formula (I), a prodrug thereof or a pharmaceutically acceptable salt thereof, or a hydrate or solvate thereof, is useful for the prevention or treatment of gout, hyperuricemia, urinary lithiasis, hyperuricemic nephropathy or the like. In the formula, n is 1 or 2; RA is a hydrogen atom or a hydroxyl group; R1 is a hydrogen atom, a hydroxyl group, a thiol group, an amino group or a chlorine atom; ring J represents an optionally substituted 2-naphthyl group, or a group represented by the following general formula (II) wherein Y represents a single bond or a connecting group; ring Z represents an optionally substituted aryl group or heteroaryl group or the like; and R2 to R4, P1 and Q represents a halogen atom, a cyano group or the like.

Bradykinin B1 antagonists: SAR studies in the 2,3-diaminopyridine series

SAR study of the biphenyl region of 2,3-diaminopyridine bradykinin B 1 antagonists was investigated with non-aromatic carbo- and heterocyclic rings. A piperidine ring was found to be a good replacement for the proximal phenyl ring while replacement of the distal phenyl was optimal with a cyclohexyl group leading to a dramatic improvement in affinity for the B 1 receptor.

PYRAZOLOPYRIMIDINES AS CYCLIN-DEPENDENT KINASE INHIBITORS

In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs using such compounds or pharmaceutical compositions.